Monitoring microarray-based gene expression profile changes in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 18, 2005, Pages 2811-2816

  Mao, Hong Ju ^a   Li, Hong Nian ^b   Zhou, Xiao Mei ^b   Zhao, Jian Long ^a   Wan, Da Fang ^a  

^a SHANGHAI INSTITUTE OF MICROSYSTEM AND INFORMATION TECHNOLOGY   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

cDNA microarray; Gene expression profile; Hepatocellular carcinoma

Indexed keywords

ARTICLE; BIOLOGICAL MONITORING; CANCER GROWTH; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; DNA PROBE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NICK END LABELING; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 18944367838     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i18.2811     Document Type: Article

References (27)

1. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsunobu M, Ishikawa T, Nakagama H, Harada H. Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991; 51: 89-93
2. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocelluar carcinoma. Toxicology 2002; 181-182: 43-47
3. Okada T, Iizuka N, Yamada-Okabe H, Mori N, Tamesa T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S, Hamamoto Y, Oka M. Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett 2003; 555: 583-590
4. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11: 447-449
5. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999; 154: 981-986
6. Degot S, Regnier CH, Wendling C, Chenard MP, Rio MC, Tomasetto C. Metastatic Lymph Node 51, a novel nucleocytoplasmic protein overexpressed in breast cancer. Oncogene 2002; 21: 4422-4434
7. Yan HX, He YQ, Dong H, Zhang P, Zeng JZ, Cao HF, Wu MC, Wang HY. Physical and functional interaction between receptor-like protein tyrosine phosphatase PCP-2 and beta-catenin. Biochemistry 2002; 41: 15854-15860
8. Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 2002; 62: 283-289
9. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 1992; 257: 1685-1689
10. Horiuchi K, Weskamp G, Lum L, Hammes HP, Cai H, Brodie TA, Ludwig T, Chiusaroli R, Baron R, Preissner KT, Manova K, Blobel CP. Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol 2003; 23: 5614-5624
11. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998; 79: 179-192
12. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998; 128: 1845-1854
13. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. J Am Med Assoc 1996; 276: 1957-1963
14. Mostert V. Selenoprotein P: properties, functions, and regulation. Arch Biochem Biophys 2000; 376: 433-438
15. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999; 20: 1657-1666
16. Coppock DL, Cina-Poppe D, Gilleran S. The quiescin Q6 gene (QSCN6) is a fusion of two ancient gene families: thioredoxin and ERV1. Genomics 1998; 54: 460-468
17. Gozani O, Patton JG, Reed R. A novel set of spliceosome-associated proteins and the essential splicing factor PSF bind stably to pre-mRNA prior to catalytic step II of the splicing reaction. Embo J 1994; 13: 3356-3367
18. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C, Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996; 381: 80-82
19. Straub T, Grue P, Uhse A, Lisby M, Knudsen BR, Tange TO, Westergaard O, Boege F. The RNA-splicing factor PSF/p54 controls DNA-topoisomerase I activity by a direct interaction. J Biol Chem 1998; 273: 26261-26264
20. Straub T, Knudsen BR, Boege F. PSF/p54 (nrb) stimulates "jumping" of DNA topoisomerase I between separate DNA helices. Biochemistry 2000; 39: 7552-7558
21. Basu A, Dong B, Krainer AR, Howe CC. The intracisternal A-particle proximal enhancer-binding protein activates transcription and is identical to the RNA- and DNA-binding protein p54nrb/NonO. Mol Cell Biol 1997; 17: 677-686
22. Traish AM, Huang YH, Ashba J, Pronovost M, Pavao M, McAneny DB, Moreland RB. Loss of expression of a 55 kDa nuclear protein (nmnt55) in estrogen receptor-negative human breast cancer. Diagn Mol Pathol 1997; 6: 209-221
23. Yang L, Embree LJ, Tsai S, Hickstein DD. Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing. J Biol Chem 1998; 273: 27761-27764
24. Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D, Hamoudi R, Linehan WM, Shipley J, Cooper CS. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997; 15: 2233-2239
25. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305
26. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-470
27. Khan J, Bittner ML, Chen Y, Meltzer PS, Trent JM. DNA microarray technology: the anticipated impact on the study of human disease. Biochim Biophys Acta 1999; 1423: M17-28